APA aipamena

Sicard, H., Bonnafous, C., Morel, A., Bagot, M., Bensussan, A., & Marie-Cardine, A. (2015). A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology.

Chicago Style aipamena

Sicard, Hélène, Cécile Bonnafous, Ariane Morel, Martine Bagot, Armand Bensussan, and Anne Marie-Cardine. "A Novel Targeted Immunotherapy for CTCL Is On Its Way: Anti-KIR3DL2 MAb IPH4102 Is Potent and Safe in Non-clinical Studies." Oncoimmunology 2015.

MLA aipamena

Sicard, Hélène, et al. "A Novel Targeted Immunotherapy for CTCL Is On Its Way: Anti-KIR3DL2 MAb IPH4102 Is Potent and Safe in Non-clinical Studies." Oncoimmunology 2015.